-
EHDN 2026 Part 1: What’s next in the Huntington’s disease treatment pipeline?
9 min read
Latest News
-
Skyhawk’s drug trial takes flight in the US
4 min read
Skyhawk’s FALCON-HD trial has dosed the first participants in the US with the drug, SKY-0515. The once-daily pill targets two drivers of HD, but does it actually slow disease? That’s the big question this study hopes to answer.
-
Improving Huntington's disease clinical trial recruitment through patient and family education
5 min read
How can we improve recruitment into Huntington's disease clinical trials? Talking directly with families works!
-
Chubby mice reveal the importance of the hypothalamus in Huntington's disease
6 min read
Huntington's disease mice are fat but HD patients lose weight – is a brain area called the hypothalamus to blame?
-
The genetic 'gray area' of Huntington's disease: what does it all mean?
8 min read
Intermediate alleles and reduced penetrance – the genetic 'gray area' of Huntington’s disease, explained
-
Dimebon fails in late-stage human HD clinical trial
3 min read
Dimebon fails to improve symptoms in HD patients in the HORIZON trial
-
FDA: further trial needed for Huntexil approval in HD
2 min read
Bad news for Huntexil – the FDA requires another trial before it can be approved in the US
-
Successful gene therapy trial in Parkinson’s Disease gives hope for HD
5 min read
Success for brain ‘gene therapy’ in Parkinson’s disease – good news for similar treatments being developed in HD
-
Gene silencing for HD: the story so far
10 min read
Is gene silencing as exciting as it sounds for HD, and what might the future hold?
-
Interview: Graeme Bilbe, Global Head for Neuroscience at Novartis
7 min read
HDBuzz interviews Graeme Bilbe, Global Head for Neuroscience at pharmaceutical giant Novartis, about their HD researc
-
What do sheep brains have to do with HD?
7 min read
How smart are sheep, and why do HD researchers care?
-
Interview: CHDI Management
11 min read
HDBuzz interviews three top scientists from CHDI, the biggest funder and driver of HD research worldwide
HDBuzz Trial Tracker
FDA accepts BLA for Priority Review, with a target decision date of 1 May 2027.
Show 8 more Show less
Updates from the ongoing Phase 3 INVEST-HD trial of votoplam
Updates from the Phase 1b/2a REGEN4HD trial of neural stem cell therapy hNSC-01
Updates from the ongoing Phase 2/3 FALCON-HD trial of SKY-0515
